Ultime notizie per Fitell (NASDAQ:FTEL) Azioni

Fitell

Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.

Fitell Corp

Baird analyst David Manthey downgrades GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Outperform to Neutral and raises the price target from $93 to $95.

News

Downgrades

Price Target

Analyst Ratings

Baird Downgrades GMS to Neutral, Raises Price Target to $95

(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration&nbsp;(FDA)-approved therapies, today announced the successful completion of SELVA, a Phase 3 trial of QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs). The Phase 3 trial enrolled 51 subjects, exceeding the original target of 40 subjects by over 25%.
Top-line results from SELVA are expected in the first quarter of 2026, with a New Drug Application submission planned for the second half of 2026.

PVLA

Palvella Completes Enrollment In Phase 3 SELVA Trial Of QTORIN Rapamycin For Microcystic Lymphatic Malformations, Exceeding Target Of 40 Subjects By Over 25%

Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025.

ARWR

Arrowhead Wraps Enrollment for 3 Key Trials on Fat-Busting Drug, Eyes FDA Decision in November

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and raises the price target from $3 to $8.

BTAI

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Raises Price Target to $8

JP Morgan analyst Daniel Politzer initiates coverage on Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) with a Neutral rating and announces Price Target of $16.

Initiation

JP Morgan Initiates Coverage On Host Hotels & Resorts with Neutral Rating, Announces Price Target of $16

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update with a focus on the progress made on the ATH434 development program in Multiple System Atrophy since the Company released positive Phase 2 data in January.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity CEO to Share Updates on MSA Drug at Investor Fireside Chat

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Hamzah Mazari downgraded Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from Buy to Hold and lowered the price target from $146 to $135. Bright Horizons Family shares closed at $122.33 on Friday. <a href="https://www.benzinga.com/quote/bfam/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Anthony Paolone downgraded the rating for Howard Hughes Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) from Overweight to Neutral and lowered the price target from $82 to $76. Howard Hughes shares closed at $69.26 on Friday. <a href="https://www.benzinga.com/quote/hhh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Fermium Research analyst Frank Mitsch downgraded Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Buy to Hold and announced a $30 price target. Dow shares closed at $27.76 on Friday. <a href="https://www.benzinga.com/quote/dow/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sangita Jain downgraded the rating for KBR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) from Overweight to Sector Weight. KBR shares closed at $48.93 on Friday. <a href="https://www.benzinga.com/quote/kbr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller downgraded Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Neutral to Underweight and slashed the price target from $55 to $50. Lineage shares closed at $44.76 on Friday. <a href="https://www.benzinga.com/quote/line/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23072441/image-331-1024x557.png" alt="" class="wp-image-957973" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23072441/image-331-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23072441/image-331-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23072441/image-331-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23072441/image-331.png 1172w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

BFAM

LINE

This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW))) ("Lottery.com" or "the Company") received formal notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 (the "Rule"). The Company met this requirement by maintaining a closing bid price of $1.00 or higher for twenty consecutive business days from May 21 through June 18, 2025. Nasdaq has officially closed the matter.

LTRY

LTRYW

Lottery.com Regains Nasdaq Compliance After Sustained $1.00 Bid Price

JP Morgan analyst Daniel Politzer initiates coverage on Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Overweight rating and announces Price Target of $282.

JP Morgan Initiates Coverage On Hilton Worldwide Holdings with Overweight Rating, Announces Price Target of $282

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) with a Buy rating and announces Price Target of $26.

SEPN

HC Wainwright & Co. Initiates Coverage On Septerna with Buy Rating, Announces Price Target of $26

CARM

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

On Friday, June 20, U.S. markets closed mixed amid heightened Iran-Israel tensions and uncertainty over possible U.S. involvement. Choppy trading, triple-witching volume, and inflation concerns weighed on sentiment. While the S&amp;P dipped, the Nasdaq gained for the week. Tech megacaps dragged indices lower as investors remained cautious. Mixed Fed comments added to market unease over interest rate direction.
In economic data, the Philadelphia Fed Manufacturing Index held steady at minus 4.0 in June, matching the previous reading and falling short of the expected minus 1.
Most S&amp;P 500 sectors fell Friday, led by health care, materials, and communications, while energy and consumer staples gained.
The Dow rose 0.08% to 42,206.82, the S&amp;P 500 was down 0.22% to 5,967.84, and the Nasdaq dropped 0.51% to 19,447.41.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Monday, Japan&#8217;s Nikkei 225 closed 0.01% lower at 38,401.00, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.36% at 8,474.90.
India&#8217;s Nifty 50 was down 0.62% at 24,954.30, and the Nifty 500 declined 0.23% to 22,987.20.
China&#8217;s Shanghai Composite was up 0.65% at 3,381.58, and Shanghai Shenzhen CSI 300 rose 0.29% to 3,857.90.
Hong Kong&#8217;s Hang Seng closed the session 0.67% higher at 23,689.13.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 0.27%.
Germany&#8217;s DAX index declined 0.44%.
France&#8217;s CAC 40 fell 0.48%.
U.K.&#8217;s FTSE 100 index traded lower by 0.01%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading higher by 0.99% at $74.58/bbl, and Brent was up 1.04% at $76.30/bbl.
Oil hit five-month highs as the U.S. joined Israel in striking Iran, raising supply fears. Prices later flattened as no disruptions occurred, but the risk premium persists amid Hormuz closure threats.
Natural gas rose 0.94% to $3.986.
Gold traded lower by 0.13% to $3,381.60, Silver rose 0.34% to $36.135, and Copper declined 0.67% to $4.8000.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures rose 0.11%, the S&amp;P 500 gained 0.22%, and the Nasdaq 100 was up 0.23%.
<h2 class="wp-block-heading">Forex</h2>
As of 05:45 AM ET, the U.S. Dollar Index gained 0.59% to 99.29, USD/JPY was up 1.19% to 147.84, and USD/AUD rose 1.12% to 1.5677
The U.S. dollar strengthened as investors sought safety amid Middle East tensions, especially after strikes on Iran. Moves were muted as markets awaited Iran&#8217;s response.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips As Oil Hits $75 - Global Markets Today While US Slept

Benchmark analyst David Williams reiterates Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) with a Buy and maintains $3 price target.

Reiteration

PRSO

Benchmark Reiterates Buy on Peraso, Maintains $3 Price Target

PLUS

ePlus To Sell Domestic Financing Subsidiaries To PEAC Solutions, Repositioning As Pure-Play Technology Solutions Provider

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) with a Buy and maintains $9 price target.

LCTX

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

JP Morgan analyst Daniel Politzer initiates coverage on Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Underweight rating and announces Price Target of $124.

JP Morgan Initiates Coverage On Choice Hotels Intl with Underweight Rating, Announces Price Target of $124

Award-winning Black Hornet unmanned aerial system is deployed in more than 45 countries

Teledyne FLIR's Black Hornet 4 Nano-Drone Approved For Blue UAS List Following NDAA And Cybersecurity Verification

Forte Biosciences, Inc. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=ea891ed7d5d480fe423068ec390705f6">www.fortebiorx.com</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101).
The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call.
Please connect to the call using the following link: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Flifescievents.com%2Fevent%2Fjgs927tsivn4w038%2F&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=https%3A%2F%2Flifescievents.com%2Fevent%2Fjgs927tsivn4w038%2F&amp;index=2&amp;md5=6522294948f67a8efcb35580dba86ff5">https://lifescievents.com/event/jgs927tsivn4w038/</a>. The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fortebiorx.com%2Finvestor-relations%2Fdefault.aspx&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.fortebiorx.com%2Finvestor-relations%2Fdefault.aspx&amp;index=3&amp;md5=5175b703811fc969ec4f1fc33724ee33">https://www.fortebiorx.com/investor-relations/default.aspx</a>. An archived webcast will be available on the company's website following the event.
The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms.
FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099).
The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects.
The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo.
Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject).
There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm.
"We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026." said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. "These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026."

FBRX

Forte Biosciences Reports Results in Celiac Disease Trial, Paving Way for Phase 2 in 2026

<ul>
<li>$2.2 million gross proceeds from warrant inducement transaction</li>
<li>$2.6 million gross proceeds from additional warrant exercises</li>
</ul>
MIAMI, June 23, 2025 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454291-1&amp;h=3593078241&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Finnovative-eyewear-inc-announces-exercise-of-warrants-302236683.html%23financial-modal&amp;a=LUCY">LUCY</a>), the manufacturer of smart eyewear under the Lucyd&#xAE;, Lucyd Armor&#xAE;, Reebok&#xAE;, Eddie Bauer&#xAE; and Nautica&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 746,782&nbsp;shares of the Company's common stock originally issued by the Company on April 14, 2025, at the current exercise price of&nbsp;$2.60&nbsp;per share. The closing of the warrant inducement transaction is expected to occur on or about&nbsp;June 24, 2025, subject to satisfaction of customary closing conditions. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287142).
The gross proceeds to the Company from the exercise of the warrants in the warrant inducement transaction are expected to be approximately&nbsp;$2.2 million, prior to deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.
In addition, over the last 30 days the Company has received aggregate gross proceeds of approximately $2.6 million from the exercise of certain warrants in the ordinary course by investors. Such investors exercised warrants to purchase an aggregate of 986,532 shares of the Company's common stock originally issued by the Company on April 14, 2025, at the original exercise price of $2.60 per share.

LUCY

Innovative Eyewear Enters Into Definitive Agreements For Immediate Exercise Of 746,782 Warrants At $2.60 Per Share

JP Morgan analyst Michael Mueller downgrades Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Neutral to Underweight and lowers the price target from $55 to $50.

JP Morgan Downgrades Lineage to Underweight, Lowers Price Target to $50

Press Releases

Fitell Corporation Announces $10.0 Million Registered Direct Offering

Fitell Corporation Announces Updated Registered Direct Offering for up to $10.0 Million

Fitell Corporation Announces Closing of Registered Direct Offering for up to $10.0 Million

Fitell Corporation Announces that it will hold its Extraordinary General Meeting of Shareholders on Apri 9, 2025

Fitell Corporation Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

FTEL

BARK

Big 5 Sporting Goods Corporation - Common Stock

Big 5 Sporting Goods

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Boqii Holding Limited American Depositary Shares (each representing one hundred fifty (150) Class A Ordinary Shares)

Comments

Fitell

Notizie

Ultime notizie per Fitell (NASDAQ:FTEL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO